Literature DB >> 3672438

Heparin degradation in the endothelial cells.

T Barzu1, J L van Rijn, M Petitou, G Tobelem, J P Caen.   

Abstract

We analyzed the molecular weight distribution of (125I) heparin fractions bound or internalized by human endothelial cells, using gel permeation chromatography. Our results showed that high molecular weight heparin chains are selectively bound and internalized by endothelial cells. Endocytosis is followed by depolymerization of internalized heparin. Chloroquine prevented depolymerization of internalized heparin, indicating that lysosomal enzymes are involved in this process. Degradation of high molecular weight heparin chains by endothelial cells may contribute to the inactivation of the drug, especially as concerns the antifactor IIa activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3672438     DOI: 10.1016/0049-3848(87)90365-3

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  12 in total

1.  Vascular scaffolds with enhanced antioxidant activity inhibit graft calcification.

Authors:  Bin Jiang; Rachel Suen; Jiao-Jing Wang; Zheng J Zhang; Jason A Wertheim; Guillermo A Ameer
Journal:  Biomaterials       Date:  2017-08-14       Impact factor: 12.479

Review 2.  Heparin dose response is independent of preoperative antithrombin activity in patients undergoing coronary artery bypass graft surgery using low heparin concentrations.

Authors:  Sean Garvin; Daniel Fitzgerald; Jochen D Muehlschlegel; Tjörvi E Perry; Amanda A Fox; Stanton K Shernan; Charles D Collard; Sary Aranki; Simon C Body
Journal:  Anesth Analg       Date:  2010-02-08       Impact factor: 5.108

3.  Characterization of [3H]-heparin binding in human vascular smooth muscle cells and its relationship to the inhibition of DNA synthesis.

Authors:  M K Patel; J S Refson; M Schachter; A D Hughes
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

Review 4.  Initial anticoagulation in patients with pulmonary embolism: thrombolysis, unfractionated heparin, LMWH, fondaparinux, or DOACs?

Authors:  Jenneke Leentjens; Mike Peters; Anne C Esselink; Yvo Smulders; Cornelis Kramers
Journal:  Br J Clin Pharmacol       Date:  2017-07-09       Impact factor: 4.335

Review 5.  Pharmacokinetic optimisation of the treatment of deep vein thrombosis.

Authors:  A Iorio; G Agnelli
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

6.  Hepatic uptake of a modified low molecular weight heparin in rats.

Authors:  G Stehle; E A Friedrich; H Sinn; A Wunder; J Harenberg; C E Dempfle; W Maier-Borst; D L Heene
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

7.  Heparin enhances angiogenesis by a systemic mode of action.

Authors:  K Norrby; J Sörbo
Journal:  Int J Exp Pathol       Date:  1992-04       Impact factor: 1.925

8.  The human hyaluronan receptor for endocytosis (HARE/Stabilin-2) is a systemic clearance receptor for heparin.

Authors:  Edward N Harris; Janet A Weigel; Paul H Weigel
Journal:  J Biol Chem       Date:  2008-04-22       Impact factor: 5.157

Review 9.  Heparin pharmacokinetics and pharmacodynamics.

Authors:  R J Kandrotas
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 10.  Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.

Authors:  M Verstraete
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.